has been recapitalized by
ABOUT THE COMPANY:
SDS Rx (“SDS”), a provider of healthcare delivery services, specializes in the movement of pharmaceuticals from wholesale distributors to pharmacies, as well as from long-term care (“LTC”) pharmacies to LTC facilities. SDS leverages an asset-light model and executes its deliveries through a network of independent contractors. The Company enjoyed strong historical growth through its value-added operational model and its focus on pharmaceutical products.
The SDS management team was seeking a value-add partner to help recapitalize the business and execute its clear growth strategy.
G2 was engaged to analyze and advise on potential strategic alternatives, as well as to identify and pursue potential growth opportunities – including sourcing capital from the traditional debt lending and private equity markets. Management ultimately selected a majority recapitalization and called on G2 to run a high-touch process to successfully execute the transaction.
The transaction was successfully executed in May 2018 through a recapitalization with HCI Equity Partners.